Triozzi P L, Sedwick W D, Iland H J, Richards R G, Laszlo J
J Biol Response Mod. 1986 Dec;5(6):562-70.
Activity of the interferon-induced enzyme 2',5'-oligoadenylate (2-5A) synthetase was measured in peripheral blood mononuclear cells (PBMC) of 32 cancer patients treated with recombinant human gamma-interferon (rHGIF). Pretreatment activities varied widely but remained constant for each individual. The minimum dose of rHGIF that consistently stimulated activity was 12 MU/m2, although in some patients as little as 0.004 MU/m2 was stimulatory. Enzyme activity in responding patients increased threefold at 24 h after the initial infusion and remained elevated nearly twofold at 72 h independent of dose. This increase is less than that observed after infusions of alpha-interferon and parallels results observed in vitro. Pretreatment enzyme activity did not correlate with response. Twenty-minute infusions of a fixed dose were as effective as four- and 24-h infusions in raising enzyme levels. The level of activity achieved after the initial infusion could not be sustained with twice-weekly infusions. We conclude that rHGIF does induce 2-5A synthetase activity in PBMC but not to the levels induced by alpha-interferon. The observation that brief infusions of low doses can be maximally stimulatory in vivo suggests that the response of PBMC in vivo is being confounded by factors yet to be determined. Furthermore, it appears that the capacity of PBMC to maximally respond to rHGIF in vivo, with increases in enzyme activity, is transient.
在32例接受重组人γ干扰素(rHGIF)治疗的癌症患者的外周血单核细胞(PBMC)中,检测了干扰素诱导酶2',5'-寡腺苷酸(2-5A)合成酶的活性。治疗前的活性差异很大,但每个个体保持恒定。持续刺激活性的rHGIF最小剂量为12 MU/m2,尽管在一些患者中低至0.004 MU/m2也具有刺激作用。有反应的患者在首次输注后24小时酶活性增加了三倍,在72小时时保持近两倍的升高,且与剂量无关。这种增加小于输注α干扰素后观察到的增加,并且与体外观察到的结果相似。治疗前的酶活性与反应无关。固定剂量的20分钟输注在提高酶水平方面与4小时和24小时输注一样有效。首次输注后达到的活性水平不能通过每周两次的输注维持。我们得出结论,rHGIF确实能诱导PBMC中的2-5A合成酶活性,但未达到α干扰素诱导的水平。低剂量短暂输注在体内可产生最大刺激作用这一观察结果表明,PBMC在体内的反应受到尚未确定的因素的干扰。此外,PBMC在体内对rHGIF产生最大反应并伴有酶活性增加的能力似乎是短暂的。